2.4.2.3 Class­es of Antihy­per­ten­sive Med­i­ca­tions.

Ini­tial treat­ment for hy­per­ten­sion should in­clude any of the drug class­es demon­strat­ed to re­duce car­dio­vas­cu­lar events in pa­tients with di­a­betes: ACE in­hibitors (52,53), ARBs (52,53), thi­azide-‍like di­uret­ics (54), or di­hy­dropy­ri­dine cal­ci­um chan­nel block­ers (55). For pa­tients with al­bu­min­uria (urine albumin-to-cre­a­ti­nine ratio ≥30 mg/g), ini­tial treat­ment should in­clude an ACE in­hibitor or ARB in order to re­duce the risk of pro­gres­sive kid­ney dis­ease (17) (Fig. 10.1). In the ab­sence of al­bu­min­uria, risk of pro­gres­sive kid­ney dis­ease is low, and ACE in­hibitors and ARBs have not been found to af­ford su­pe­ri­or car­dio­pro­tec­tion when com­pared with thi­azide-‍like di­uret­ics or di­hy­dropy­ri­dine cal­ci­um chan­nel block­ers (56). β-‍Block­ers may be used for the treat­ment of prior MI, ac­tive angi­na, or heart fail­ure but have not been shown to re­duce mor­tal­i­ty as blood pres­sure-‍low­er­ing agents in the ab­sence of these con­di­tions (23,57).